Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $489M | $561M | $782M | $1.11B | $1.56B | $1.77B | $1.12B | $1.05B | $1.04B | $743M |
| Revenue growth | — | 14.8% | 39.5% | 41.4% | 40.6% | 14.0% | -37.0% | -6.1% | -0.5% | -28.8% |
| Gross profit | — | — | — | — | $916M | $891M | $383M | $318M | — | — |
| Gross margin | — | — | — | — | 58.9% | 50.3% | 34.3% | 30.3% | — | — |
| Operating income | $106M | $124M | $89.8M | $114M | $434M | $341M | -$170M | -$726M | -$109M | $100M |
| Operating margin | 21.6% | 22.2% | 11.5% | 10.3% | 27.9% | 19.2% | -15.2% | -69.2% | -10.4% | 13.5% |
| Net income | $51.8M | $82.6M | $62.7M | $54.5M | $305M | $220M | -$212M | -$761M | -$191M | $52.6M |
| Net margin | 10.6% | 14.7% | 8.0% | 4.9% | 19.6% | 12.4% | -18.9% | -72.5% | -18.3% | 7.1% |
| EPS (diluted) | $1.13 | $1.71 | $1.22 | $1.04 | $5.67 | $4.06 | -$4.22 | -$14.85 | -$3.60 | $0.93 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $54.6M | $208M | $41.8M | $188M | $536M | $320M | -$34.1M | -$206M | $58.7M | $171M |
| Capital expenditures | $76.2M | $54.8M | $72.1M | $86.9M | $141M | $224M | $116M | $51.6M | $22.9M | $13.8M |
| Free cash flow | -$21.6M | $153M | -$30.3M | $101M | $395M | $96.1M | -$150M | -$258M | $35.8M | $157M |
| Share buybacks | $0.00 | $33.1M | $100K | $0.00 | $0.00 | $106M | $82.1M | $0.00 | $0.00 | $24.9M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $272M | $178M | $112M | $168M | $621M | $576M | $643M | $112M | $99.5M | $205M |
| Total assets | $970M | $1.07B | $2.23B | $2.33B | $2.88B | $2.96B | $3.17B | $1.82B | $1.39B | $1.32B |
| Total liabilities | $374M | $158M | $1.22B | $1.24B | $1.44B | $1.34B | $1.78B | $1.17B | $907M | $796M |
| Long-term debt | $248M | $13.5M | $785M | $798M | $841M | $809M | $449M | $447M | $664M | $572M |
| Shareholders' equity | $596M | $912M | $1.01B | $1.09B | $1.45B | $1.61B | $1.39B | $649M | $483M | $523M |
| Retained earnings | $254M | $337M | $367M | $422M | $727M | $958M | $739M | -$21.8M | -$212M | -$160M |
| Shares (wtd avg diluted) | 49.3M | 50.3M | 51.4M | 52.4M | 53.8M | 54.1M | 50.1M | 51.2M | 53.0M | 56.7M |
Every figure is extracted from Emergent BioSolutions Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.